Indicators
Indicators
Value
Direction
MACD(12,26,9)
-3.806
Neutral
RSI(14)
39.409
Neutral
STOCH(KDJ)(9,3,3)
16.313
Sell
ATR(14)
4.852
Low Volatility
CCI(14)
-137.652
Sell
Williams %R
98.449
Oversold
TRIX(12,20)
-0.061
Sell
StochRSI(14)
7.715
Sell
Search
Mirum Pharmaceuticals Inc
MIRMAdd to Watchlist
105.950USD
-6.640-5.90%
Close 07-31 16:00（ET）Quotes delayed by 15 min
5.50BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-5.90%
5 Days
-6.26%
1 Month
-9.50%
6 Months
+2.64%
Year to Date
+34.13%
1 Year
+105.01%
Key Figures
113.250Open
113.460High
578.74KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.12%Turnover Ratio
112.590Prev. Close
105.700Low
47.70MTurnover
LossP/E Static
17.47P/B
0.00%Div Yield TTM
-101.04%ROA
114.99052wk High
1.07Volume Ratio
-87.94MNet Profit
51.90MShares
-13.5916EPS TTM
0.50Beta
-335.82%ROE
43.30052wk Low
6.89%Amplitude
81.98%Gross Margin
5.50BMarket Cap
-2.75Reward/Risk
2.78%Risk Rate
TradingKey Stock Score of Mirum Pharmaceuticals Inc
Currency: USD Updated: 2026-07-31Key Insights
Mirum Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 7 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 147.69.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mirum Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Mirum Pharmaceuticals Inc Highlights
StrengthsRisks
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 179.71% year-on-year.
Fairly Valued
The company’s latest PE is -7.80, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 68.01M shares, increasing 6.60% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.02.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
147.692
Target Price
+37.30%
Upside Space
Mirum Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
14
analysts
Buy
Current Rating
147.692
Target Price
+37.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Mirum Pharmaceuticals Inc
MIRM
14
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
110.508
Sell
MA10
112.808
Sell
MA20
117.693
Sell
MA50
109.367
Sell
MA100
102.730
Buy
MA200
92.506
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mirum Pharmaceuticals Inc Info
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Ticker SymbolMIRM
CompanyMirum Pharmaceuticals Inc
CEOPeetz (Christopher)
Websitehttps://mirumpharma.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Mirum Pharmaceuticals Inc (MIRM)?
The current price of Mirum Pharmaceuticals Inc (MIRM) is 105.92.
What is the symbol of Mirum Pharmaceuticals Inc?
The ticker symbol of Mirum Pharmaceuticals Inc is MIRM.
What is the 52-week high of Mirum Pharmaceuticals Inc?
The 52-week high of Mirum Pharmaceuticals Inc is 114.99.
What is the 52-week low of Mirum Pharmaceuticals Inc?
The 52-week low of Mirum Pharmaceuticals Inc is 43.30.
What is the market capitalization of Mirum Pharmaceuticals Inc?
The market capitalization of Mirum Pharmaceuticals Inc is 6.45B.
Is Mirum Pharmaceuticals Inc (MIRM) currently rated as Buy, Hold, or Sell?
According to analysts, Mirum Pharmaceuticals Inc (MIRM) has an overall rating of Buy, with a price target of 147.69.
What is the Earnings Per Share (EPS TTM) of Mirum Pharmaceuticals Inc (MIRM)?
The Earnings Per Share (EPS TTM) of Mirum Pharmaceuticals Inc (MIRM) is -0.47.